| Literature DB >> 24999376 |
Matthias R Meyer1, Eric R Prossnitz2, Matthias Barton3.
Abstract
Natural estrogens such as 17β-estradiol are endogenous vasodilators and have been implicated in the gender differences of hypertension. These hormones activate estrogen receptors ERα and ERβ, which mediate part of estrogen-dependent vasodilation. In addition, a novel G protein-coupled estrogen-binding receptor termed GPER/GPR30 has been identified that is expressed in the cardiovascular system. Using knock-out animals or drugs selectively targeting GPER/GPR30, a significant role for this receptor as a mediator of acute estrogen-dependent vasodilation involving nitric oxide (NO) and blood pressure-lowering activity has been demonstrated. The accumulating evidence that GPER/GPR30 is responsible for control of vascular tone indicates that this receptor may represent a novel drug target for pharmacologic treatment of hypertension in postmenopausal women and possibly also men.Entities:
Keywords: Blood Pressure; Endothelium; Hormone Therapy; Hypertension; Menopause; Nitric Oxide; Vasodilation
Year: 2011 PMID: 24999376 PMCID: PMC4079007 DOI: 10.2174/1871522211108040255
Source DB: PubMed Journal: Immunol Endocr Metab Agents Med Chem ISSN: 1871-5222